Impact of Resection Margin Width on Local Control and Prognostic Factors in HER2-enriched and Triple-negative Breast Cancer in the Modern Systemic Treatment Era
Anticancer Research · 2026
DOI: 10.21873/anticanres.18410 ↗Kurz gefasst
Fachartikel in der Zeitschrift Anticancer Research, 2026. Verfasst von Won Ick Chang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Seoul National University Hospital, Seoul, Republic of Korea. Hauptthemen laut MEDLINE: Margins of Excision, Erb-b2 Receptor Tyrosine Kinases, Mastectomy, Segmental, Triple Negative Breast Neoplasms.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Radiation Oncology, Seoul National University Hospital, Seoul, Republic of Korea.
- Department of Radiation Oncology, Seoul National University Bundang Hospital, Seoul, Republic of Korea.
- Department of Radiation Oncology, Seoul National University Hospital, Seoul, Republic of Korea; radiat@snu.ac.kr.
Zitieren
APA
Chang, W. I., Jang, B. S., Chang, J. H., Kim, K., & Shin, K. H. (2026). Impact of Resection Margin Width on Local Control and Prognostic Factors in HER2-enriched and Triple-negative Breast Cancer in the Modern Systemic Treatment Era. Anticancer Research. https://doi.org/10.21873/anticanres.18410
Vancouver
Chang WI, Jang BS, Chang JH, Kim K, Shin KH. Impact of Resection Margin Width on Local Control and Prognostic Factors in HER2-enriched and Triple-negative Breast Cancer in the Modern Systemic Treatment Era. Anticancer Research. 2026. doi:10.21873/anticanres.18410
BibTeX
@article{Chang2026,
author = {Chang, Won Ick and Jang, Bum-Sup and Chang, Ji Hyun and Kim, Kyubo and Shin, Kyung Hwan},
title = {Impact of Resection Margin Width on Local Control and Prognostic Factors in HER2-enriched and Triple-negative Breast Cancer in the Modern Systemic Treatment Era},
journal = {Anticancer Research},
year = {2026},
doi = {10.21873/anticanres.18410}
}
EUVIMED